|
1 Indications And Usage Balversa Is Indicated For The Treatment Of Adult Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Muc), That Has: Susceptible Fgfr3 Or Fgfr2 Genetic Alterations, And Progressed During Or Following At Least One Line Of Prior Platinum-Containing Chemotherapy, Including Within 12 Months Of Neoadjuvant Or Adjuvant Platinum-Containing Chemotherapy. Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For Balversa [See Dosage And Administration (2.1) And Clinical Studies (14) ] . This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trials [See Clinical Studies (14) ] . Balversa Is A Kinase Inhibitor Indicated For The Treatment Of Adult Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Muc), That Has Susceptible Fgfr3 Or Fgfr2 Genetic Alterations And Progressed During Or Following At Least One Line Of Prior Platinum-Containing Chemotherapy Including Within 12 Months Of Neoadjuvant Or Adjuvant Platinum-Containing Chemotherapy. Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic For Balversa. ( 1 , 2.1 ) This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trials. ( 1 , 14 )
|